Abstracts Archive - Page 2135 of 2607 - ACR Meeting Abstracts

Abstract Number: 1471 • 2014 ACR/ARHP Annual Meeting
TNFα Influences the Status of B and T Cells By Acting on BCR and TCR Pathways Via RasGRP1 and RasGRP3 Proteins
Marie-Laure Golinski¹, Martine Hiron², Céline Derambure², Clément Guillou¹, Manuel Fréret², Olivier Boyer³, Olivier Vittecoq⁴ and Thierry Lequerré⁵, ¹Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen, France, ³Immunology, INSERM U905, University of Rouen, Rouen, France, ⁴Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵1 Rue De Germont, Chu De Rouen, Rouen, France
Background/Purpose Rheumatoid arthritis (RA) is the most common inflammatory arthritis. B and T cells play a key role in the RA pathophysiology. RasGRP is a…
Abstract Number: 1470 • 2014 ACR/ARHP Annual Meeting
Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti-Malondialdehyde-Acetaldehyde Antibody in Rheumatoid Arthritis
Geoffrey Thiele¹, Michael J. Duryee², Daniel Anderson³, Lynell W. Klassen⁴, Stephen Mohring⁵, Kathleen Young⁶, Dathe Benissan-Messan⁷, Harlan Sayles³, Jeremy Sokolove⁸, William H. Robinson⁹, James O' Dell³, Anthony Nicholas¹⁰ and Ted R. Mikuls³, ¹Int Med/Sec of Rheum/Immun, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁶Int Med/Sec of Rheum/Immun, University of Nebraska Medical Center, Omaha, NE, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁹VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ¹⁰Neurology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Products of oxidative stress, MAA adducts are highly immunogenic and have been associated with tolerance loss. To examine their potential role in disease-related…
Abstract Number: 1469 • 2014 ACR/ARHP Annual Meeting
Methotrexate Treatment Reduces Serum IL-6 Level By Decreasing a CD14brightCD16+ Intermediate Non-Classical Subset of Monocytes in RA Patients
Masako Tsukamoto¹, Keiko Yoshimoto², Noriyuki Seta³, Katsuya Suzuki² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine, Keio university, Tokyo, Japan
Background/Purpose It is well known that circulating monocytes are the source of inflammatory cytokines, such as IL-6 and TNFα and newly divided into three subsets…
Abstract Number: 1467 • 2014 ACR/ARHP Annual Meeting
Do G-CSF and Neutrophils Contribute to the Pathophysiology of Rheumatoid Arthritis?
Gabrielle Goldberg¹, Simon Chatfield^2,3, Jane Murphy¹, Ee Shan Pang¹, Yunshun Chen⁴, Gordon Smyth⁴, Milica Ng⁵, Michael Wilson⁵, Clare O'Neill³, Samantha Busfield⁵, Arna Andrews⁵ and Ian P. Wicks^3,6,7, ¹Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, ²Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, ³Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ⁴Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, ⁵Research, CSL Limited, Melbourne, Australia, ⁶Inflammation, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, ⁷Medical Biology, The University of Melbourne, Melbourne, Australia
Background/Purpose Rheumatoid arthritis (RA) is characterised by a persistent, but poorly understood interplay between innate and adaptive immunity. Neutrophils are the predominant cell type in…
Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting
Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA
Kazuyuki Yoshizaki, Osaka University, Osaka, Japan
Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…
Abstract Number: 1466 • 2014 ACR/ARHP Annual Meeting
Patients with Active Rheumatoid Arthritis Display an Expanded Population of GM-CSF Expressing Peripheral B Cells
Sofia Adamidi, Anastasia Makris, Christos Koutsianas, Christina Tsalapaki, Emilia Hadziyannis and Dimitrios Vassilopoulos, 2nd Department of Medicine and Laboratory of Clinical Immunology-Rheumatology, Hippokration General Hospital, University of Athens Medical School, Athens, Greece
Background/Purpose GM-CSF has been implicated in rheumatoid arthritis (RA) pathogenesis and is being investigated as a novel therapeutic target. B cells secreting GM-CSF have been…
Abstract Number: 1465 • 2014 ACR/ARHP Annual Meeting
Follicular Helper T Cells Control Autoimmunity through IL-21/IL-21 Receptor Interaction in RA Patients
Shikha Singla¹, Minzi Chen², Jerry Pounds Jr.², Omar Khan², Jerald M. Zakem², Kismet Collins², Tamika Webb-Detiege², William E. Davis², Robert Quinet² and Xin Zhang³, ¹Rheumatology, Ochner Medical Center, New Orleans, LA, ²Rheumatology, Ochsner Medical Center, New Orleans, LA, ³Institute of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovium, causing progressive joint destruction and reduction in quality of life…
Abstract Number: 1464 • 2014 ACR/ARHP Annual Meeting
Numbers of Circulating CD4 Positive CD28null T Cells Are Increased in Patients with Rheumatoid Arthritis and Are Associated with Rheumatoid Factor Positivity but Not Subclinical Cardiovascular Disease
Sarah Skeoch¹, John Waterton², Yvonne Alexander³ and Ian N. Bruce⁴, ¹Arthritis Research UK Centre for Epidemiology and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²Bioimaging Institute, University of Manchester, Manchester, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose CD4+ T cells which lack CD28 co-expression (CD28null cells) account for less than 2.5% of CD4+ T cells in healthy individuals. These cells are…
Abstract Number: 1463 • 2014 ACR/ARHP Annual Meeting
Dickkopf-1 Perpetuated Synovial Fibroblast Activation and Synovial Angiogenesis in Rheumatoid Arthritis
Li Zheng¹, Fanlei Hu², Yingni Li¹, Lianjie Shi², Xiaoxu Ma¹, Xuewu Zhang³ and Zhanguo Li⁴, ¹Peking University People's Hospital, Beijing, China, ²Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ³11 South Street, XiZhiMen , We, Peking University People's Hospital, Beijing, China, ⁴Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose . Dkk-1, a master regulator of joint remodeling, is elevated and leads to bone resorption in patients with RA. This study aimed to investigate…
Abstract Number: 1482 • 2014 ACR/ARHP Annual Meeting
Response of Patient Reported Symptoms of Stiffness and Pain during the Day from Adding Low-Dose Delayed-Release (DR) Prednisone to Stable DMARD Therapy over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA)
Rieke Alten¹, Amy Y. Grahn², Patricia Rice³, Robert Holt⁴ and Frank Buttgereit⁵, ¹Charité University Medicine, Berlin, Germany, ²Horizon Pharma, Inc., Deerfield, IL, ³Premier Research, Naperville, IL, ⁴College of Pharmacy, University of Illinois-Chicago, Vernon Hill, IL, ⁵Charité University Hospital, Berlin, Germany
Background/Purpose: RA patients experience stiffness which impacts their daily lives. Although this patient reported symptom was dropped from the RA classification criteria there is growing…
Abstract Number: 1481 • 2014 ACR/ARHP Annual Meeting
Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions
Namour Florence¹, Desrivot Julie¹, Annegret Van der Aa², Chantal Tasset³ and Gerben van 't Klooster², ¹Galapagos, Romainville, France, ²Galapagos NV, Mechelen, Belgium, ³Generaal de Wittelaan L11 A3, Galapagos NV, Mechelen, Belgium
Background/Purpose: GLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Selective inhibition of JAK1 may combine improved safety and clinical efficacy profiles with a rapid onset of…
Abstract Number: 1480 • 2014 ACR/ARHP Annual Meeting
Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach
Florence Namour¹, Chantal Tasset², Béatrice Vayssièrre³, Gerben van 't Klooster⁴, Paul Diderichsen⁵ and Eugène Cox⁶, ¹102 Avenue Gaston Roussel, Galapagos SASU, Romainville, France, ²Generaal de Wittelaan L11 A3, Galapagos NV, Mechelen, Belgium, ³Galapagos SASU, Romainville, France, ⁴Galapagos NV, Mechelen, Belgium, ⁵Quantitative Solution, Breda, Netherlands, ⁶Quantitative Solutions, Breda, Netherlands
Background/Purpose: GLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Selective inhibition of JAK1 may combine favorable safety and clinical efficacy profiles with rapid…
Abstract Number: 1479 • 2014 ACR/ARHP Annual Meeting
Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with ALX-0061: Post-Hoc Analysis of Phase I/II Data
Katrien Van Beneden¹, Katrien Verschueren¹, Wouter Willems¹, Heidi Wouters¹, Joke D'Artois¹, Katelijne De Swert¹, Steven De Bruyn¹ and Gerhard Arold², ¹Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ²Medical Affairs, PRA International GmbH, Berlin, Germany
Background/Purpose: ALX-0061 is a monovalent IL-6R targeting Nanobody, inhibiting signaling via soluble and membrane IL-6R. The safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of ALX-0061 was…
Abstract Number: 1478 • 2014 ACR/ARHP Annual Meeting
Pharmacokinetics, Bioavailability and Safety of a Modified-Release Once-Daily Formulation of Tofacitinib in Healthy Volunteers
M. Lamba¹, R. Wang¹, T. Fletcher², C. Alvey¹, A. Hazra¹, J. Kushner¹, J. Larmann¹ and T. Stock², ¹Pfizer Inc, Groton, CT, ²Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The efficacy and safety of an immediate-release (IR) formulation…
Abstract Number: 1477 • 2014 ACR/ARHP Annual Meeting
Overweight and Obesity Are Associated with Reduced Risk of Rheumatoid Arthritis in Men, but Not in Women
Carl Turesson¹, Ulf Bergström², Mitra Pikwer^2,3, Jan-Åke Nilsson² and Lennart Jacobsson^2,4, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology Unit, Mälar Hospital, Eskilstuna, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden
Background/Purpose There are diverging results on the relation between body mass index (BMI) and risk of rheumatoid arthritis (RA). Several studies have reported different patterns…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].